Nine researchers from Utrecht have received funding in the 25th round of the NWO Open Competition ENW-XS. The grants (of up to 50,000 euros) are intended to enable small-scale, innovative and risky ...

They found that a STING agonist can reactivate these pathways in breast cancer cells, but it also does so in normal cells, suggesting that this is not a good way to create a therapeutic window.

Considered to be one of the greatest revolutions in cancer treatment, immunotherapy enhances the immune system's ability to ...

allowing bacteria to proliferate within tumors and activate the body's immune response. Scientists are exploring bacteria's potential as cancer-fighting agents by genetically engineering them to ...

challenging the rejection of its application to begin Phase I human trials of its cancer immunotherapy drug, Per-C-Vax, for patients recently diagnosed with solid organ cancers. A bench of Chief ...

Current anticancer treatments essentially target the primary tumor cells that proliferate quickly, but do not effectively ...

Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics. BMS is best known as an early pioneer of ...

A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed. This crucial advance in the fight ...

May 8, 2025 — Researchers have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 ...